Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib discontinuation in radiologically undetectable oligometastatic GIST
2016-003774-40Phase 2Terminated
- Sponsor
- Oslo University Hospital
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in gastrointestinal stromal tumor (GIST), sponsored by Oslo University Hospital. Primary endpoint: Progression-free survival. Started Sep 2016; status: terminated.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2016-003774-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003774-40.